US2012160944A1PendingUtilityA1
Method for the production of commercial nanoparticle and micro particle powders
Est. expiryApr 24, 2029(~2.8 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61K 31/497A23P 10/20A61P 11/00B02C 17/20A61K 9/1623A61K 31/196A61K 9/1652A61K 47/50A61K 9/1635A61K 31/18A61K 31/565A01N 25/12A61K 31/122A61K 31/57A61K 31/198A61K 38/13A61K 9/16A01N 37/38A01N 25/10A61J 3/02B02C 19/0056A61K 9/1617A61K 31/421A61K 9/145A23P 10/30A61K 31/496A61K 31/4709A61K 9/14A61K 31/405A61K 31/5415A01N 25/34A01N 47/36A61K 31/137A61K 9/1682A23L 33/10A01N 55/02A61K 31/415A23V 2002/00A61K 31/404A61K 33/04A01N 57/20A61K 31/53A61K 9/0075A61K 9/146A61K 31/192A01N 39/04A01N 47/14A01N 57/12A01N 59/02
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.
Claims
exact text as granted — not AI-modified1 . A method for producing nanoparticle and/or microparticle biologically active material with powder handling characteristics superior to powders made by conventional size reduction processes, wherein the said method comprises the steps of:
dry milling a solid biologically active material and a millable grinding matrix in a mill comprising a plurality of milling bodies, for a time period sufficient to produce particles of the biologically active material dispersed in an at least partially milled grinding material.
2 - 47 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.